Tvardi Expands ATM by $9.7M After Burning Through $11M in Prior Sales
TVRD has more than doubled off its 52-week low of $1.5.
Summary
Tvardi Therapeutics is tapping the market again, expanding its at-the-market offering by $9.69 million after already selling $11 million in shares over the past year. The company had a $12.5 million ATM program in place; this new supplement effectively replaces it, signaling continued cash needs. With a market cap around $30 million and a going concern warning, the dilution is material. The prior ATM sales were executed at an average price well above the current $3.15, suggesting the new shares may be sold at a discount. This follows positive Phase 1 data for TTI-109 earlier this month, but the financing urgency overshadows the clinical progress.
At the time of this announcement, TVRD was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30M. The 52-week trading range was $1.50 to $43.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.